TransMedics Group, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TransMedics Group, Inc. (TMDX) on September 10, 2026. The filing discloses a leadership transition within the executive management team, specifically the appointment of a new Chief Financial Officer (CFO) and the departure of the incumbent CFO.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the transition of the Chief Financial Officer role:
- Appointment: Fernando Araujo was appointed as Chief Financial Officer and Treasurer, effective September 21, 2026.
- Departure: Gerardo Hernandez, who served as CFO since 2024, will step down from the executive role on September 21, 2026.
- Transition Plan: Mr. Hernandez will remain a non-executive employee until December 31, 2026, and serve as a non-employee senior advisor until April 30, 2027.
Compensation and Employment Terms
Fernando Araujo (Incoming CFO):
- Base Salary: $590,000 annually.
- Target Bonus: 60% of base salary (prorated for 2026).
- Sign-on Bonus: $200,000 cash, payable in two installments within the first 90 days.
- Equity Awards: Initial stock options and restricted stock units (RSUs), each with a grant date value of approximately $1,750,000.
- Severance: Entitled to 12 months of base salary and highest bonus of the prior three years if terminated without cause after 12 months of service. Enhanced severance (1.5x base salary, lump sum bonus, 18 months health coverage, full equity vesting) applies if termination occurs within 24 months of a change in control.
Gerardo Hernandez (Outgoing CFO):
- Transition Period: Continues to receive an annual base salary of $535,000 and remains eligible for the 2026 annual bonus while employed as a non-executive employee.
- Advisory Role: No additional remuneration for advisory services beyond the vesting of outstanding equity awards.
- Post-Separation: Will receive severance benefits consistent with a "without cause" termination under his existing retention agreement following the separation date.
Investor Verification Checklist
- Verify the effective date of the CFO transition (September 21, 2026) and the interim advisory period for the outgoing CFO.
- Review the full text of the Employment Agreements and Transition Agreement, which are expected to be filed as exhibits to the Form 10-Q for the quarter ended September 30, 2026.
- Assess the impact of the $200,000 sign-on bonus and $3.5 million in total equity grant value on the company's near-term compensation expense.
- Confirm the vesting schedules for the new equity awards (25% cliff vesting followed by monthly/annual installments).